State of Alaska Department of Revenue Boosts Holdings in Sotera Health (NASDAQ:SHC)

State of Alaska Department of Revenue increased its holdings in Sotera Health (NASDAQ:SHC) by 31.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,760 shares of the company’s stock after buying an additional 4,270 shares during the quarter. State of Alaska Department of Revenue’s holdings in Sotera Health were worth $296,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. CWM LLC raised its stake in Sotera Health by 86.1% during the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock worth $25,000 after acquiring an additional 993 shares during the period. GAMMA Investing LLC raised its stake in Sotera Health by 125.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after acquiring an additional 1,660 shares during the period. Point72 DIFC Ltd raised its stake in Sotera Health by 556.6% during the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after acquiring an additional 5,544 shares during the period. Acadian Asset Management LLC raised its stake in Sotera Health by 728.0% during the 2nd quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock worth $111,000 after acquiring an additional 8,248 shares during the period. Finally, Sandia Investment Management LP bought a new stake in Sotera Health during the 1st quarter worth approximately $120,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now directly owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 55.12% of the stock is currently owned by corporate insiders.

Sotera Health Stock Performance

SHC stock opened at $16.09 on Friday. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.59. The business has a 50-day moving average price of $15.98 and a 200 day moving average price of $13.74. The company has a market capitalization of $4.56 billion, a P/E ratio of 64.36 and a beta of 2.08. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.18 earnings per share. As a group, equities research analysts forecast that Sotera Health will post 0.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SHC has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a report on Tuesday, August 6th. Citigroup raised their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Barclays raised their target price on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.